AGCO Corporation vs Nuwellis Inc — how do they compare? AGCO Corporation trades at $102.25 (market cap $7.10B), while Nuwellis Inc trades at $1.5 (market cap $542.80K). The key difference: AGCO Corporation is far larger — about 13080.3× Nuwellis Inc's market cap, and AGCO Corporation pays a 1.18% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| AGCO | NUWE | |
|---|---|---|
Market Cap | $7.10B | $542.80K |
Sector | Industrials | Technology |
52-Week High | $140.49 | $220.50 |
52-Week Low | $100.14 | $1.42 |
Enterprise Value | $9.37B | -$1.27M |
Dividend Yield | 1.18% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NUWE trades at $1.49, down 8.59% over the past day, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025, with a negative net income margin of -217.22%, though it has shown revenue growth and recent strategic expansions in pediatric care. A recent 35:1 reverse stock split was executed on June 26, 2026.
The outlook remains high-risk due to persistent losses and cash burn, but growth initiatives and new product development offer potential. Key risks include execution challenges and dependence on financing. Analyst sentiment is mixed, with a 50% buy and 50% hold rating among covered analysts.
Trailing returns across standard periods
Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.
Read more on AGCO →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →